Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

mCRPC: Docetaxel-carboplatin improves outcomes after second-generation hormone therapy

Key clinical point: Addition of carboplatin to docetaxel is associated with improved response rates and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients with disease progression on abiraterone or enzalutamide.

Major finding: Patients treated with carboplatin+docetaxel were 2.6 times as likely to have a favorable response vs. those treated with docetaxel alone (odds ratio [OR], 2.625; 95% confidence interval [CI], 1.15‐5.99) and almost 3 times vs. those treated with cabazitaxel alone (OR, 2.975; 95% CI, 1.04-8.54). 30-month overall survival was significantly higher with carboplatin+docetaxel (70.7%) vs. docetaxel alone (38.9%) or cabazitaxel alone (30.3%; P = .008).

Study details: A retrospective study of 150 mCRPC patients with disease progression on enzalutamide or abiraterone; 90 patients received docetaxel alone, 33 received carboplatin+docetaxel, and 27 received cabazitaxel alone.

Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Citation:

Ahmed ME et al. Prostate. 2020 Jul 31. doi: 10.1002/pros.24048.